Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BDA202201

NGF mAb

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: NGF mAb
    Indications: Cancer pain, chemotherapy-induced neuropathic pain, Kashin-Beck disease, diabetic neuralgia, interstitial cystitis, chronic low back pain.
    Research phase: Phase Ⅰ/Ⅱa
    Cooperation demands: License-out or co-development
  • Highlights

    1. Clear MoA.
    NGF is released upon injury and causes pain by activating its receptor TrkA on nociceptors and mast cells, leading to transmission of pain signals from the periphery to the spinal cord and brain via the dorsal ganglion. And the efficacies of anti-NGF have been validated clinically in a variety of pain conditions


    2. Wide range of indications:Pain.


    Wide range of indications:Pain



    3. Excellent Phase I Data
    (1). No dose-dependent AEs have been identified in Phase I.
    (2). NGF mAb is expected to be administered every 8 weeks based on its PK profiles.



    4. Global competitiveness.
    The analgesic effect of NGF mAb is comparable to that of morphine, but it is not addictive.
    The RPOA risk can be reduced by selecting cancer-related indications and excluding OA patients.


  • Project Introduction

    1. Asset type: Humanized NGF mAb

    2. Indication: Cancer pain, chemotherapy-induced neuropathic pain, Kashin-Beck disease, diabetic neuralgia, interstitial cystitis, chronic low back pain.

    3. Research phase: Phase Ⅰ/Ⅱa

    4. Research progress:
       1) Complete the first human trial.
       2) Complete the single-dose escalation trial.
       3) Complete the PK and safety trial:

    NGF mAb is expected to be administered every 8 weeks based on its PK profiles.
    No dose-dependent AEs have been identified in Phase I.

Comments (0)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message